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cense.Abstract Introduction: Systemic lupus erythematosus (SLE) ﬂares have been linked to reproduc-
tive hormones. Prolactin hormone is involved in a number of rheumatic and autoimmune disease. It
was implicated in the pathogenesis of SLE.
Aim of the work: This study was conducted to evaluate serum prolactin level in a group of Saudi
SLE patients and to explore its correlation to clinical and laboratorial markers of disease activity.
Patients and methods: Thirty-three Saudi female patients who fulﬁlled the American College of
Rheumatology criteria for SLE were investigated. Disease activity was assessed using the published
SLEDAI. Fasting and resting basal serum prolactin and the serological and laboratory proﬁles of
the studied patients were assessed.
Results: Hyperprolactinemia was detected in 10 (30.3%) patients with a mean serum prolactin of
680.7 ± 1021 mIU/L. There were no signiﬁcant correlation between SLEDAI score and serum pro-
lactin levels. Linear regression analysis selected low platelet count and raised total leukocytic count
as the best predictors of serum prolactin level in the investigated Saudi SLE patients (R2 = 0.4,
P= 0.002).m
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78 D. ShahinConclusion: Hyperprolactinemia detected in a subset of Saudi SLE patients can be predicted by
thrombocytopenia and leukocytosis. However, it did not correlate with SLEDAI score of disease
activity.
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Systemic lupus erythematosus (SLE) is an autoimmune rheu-
matic disease that commonly affects women during childbear-
ing period. SLE ﬂares have been linked to reproductive
hormones [1,2].
Prolactin (PRL) acts as a hormone due to pituitary secre-
tion; and as a cytokine due to extrapituitary production [3].
Most of the immune cells secrete PRL which stimulate prolif-
eration, differentiation and maturation of T and B lympho-
cytes. It ampliﬁes interleukin-2 (IL-2) action and inhibits
lymphocytes apoptosis [4]. PRL, as an important immuno-
modulator, is linked with a number of rheumatic and autoim-
mune diseases [5]. It was implicated in the pathogenesis of SLE
[6–9]. Hyperprolactinemia (hPRL) was observed in SLE pa-
tients of both genders and was associated with disease activity
[10–13]. However, some studies did not support this associa-
tion [14–16]. The role of prolactin in the pathogenesis of
SLE is not yet conclusive. There is scarcity of data on PRL
and its relation to SLE from Arab countries. The Saudi com-
munity is a unique, closed community that has special social,
environmental and genetic characteristics, and this is the ﬁrst
study attempting to evaluate serum PRL level in a group of
Saudi SLE patients and to explore its relation to disease
activity and various clinical, laboratory and serological fea-
tures and comparing results with reports from other parts of
the world.2. Patients and methods
2.1. Patients
2.1.1. Inclusion criteria
Thirty-seven consecutive patients fulﬁlled the American Col-
lege of Rheumatology (ACR) criteria for SLE [17] were
studied. Patients were either inpatients or outpatients of the
Rheumatology and Immunology unit-Internal Medicine
Department, King Khalid University and Asser Central
Hospital (ACH), Abha, Saudi Arabia. The protocol was
approved by the local ethics committee of KKU and
all patients gave informed consent prior to entering the study.
This study was conducted between January 2008 and June
2009 as an observational cross-sectional survey. Demographic
characteristics, clinical features and serological proﬁles were
recorded. Disease activity was classiﬁed according to the pub-
lished SLE Disease Activity Index (SLEDAI) [18]. Patient’s
score >4 was considered as an active disease.
2.1.2. Exclusion criteria
Patients with renal and/or hepatic failure, pregnancy, hypothy-
roidism or taking medications known to affect PRL level were
excluded from the study.2.2. Measurement of serum PRL
All blood samples were drawn between 8:30–10:30 am. The
subjects under investigation were fasting and resting for at
least 30 min, then a canula was introduced with minimal
trauma into the Cubital pit vein. The blood samples were
drawn after another 30 min. Intervals of 30 min were chosen
because PRL is a stress hormone that is released in repeated
pulses and the biological half life of PRL is 20–30 min [19].
Basal PRL was determined by immuno-radiometric assay
(IRMA). Normal levels of serum PRL in ACH laboratory
were (72–511 mIU/L) for females and (86–390 mIU/L) for
males.2.3. Measurement of autoantibodies and other markers of
disease activity
Anti ds DNA, complement (C3–C4) and anticardiolipin anti-
bodies were measured by enzyme-linked immuno-sorbent as-
say (ELISA). Erythrocyte sedimentation rate (ESR),
Complete blood count (CBC) and 24 h urinary protein were
recorded.
Statistics. Data were analyzed using the statistical package
SPSS version 17.0. Data were expressed as means ± standard
deviation (SD), median and frequencies. Group differences
were compared by using t-test, one way ANOVA, X2,
Mann-Whitney and Fisher’s exact test when applicable. Pear-
son’s correlation coefﬁcient (r) between variables was calcu-
lated. Linear regression analysis was performed. Serum PRL
level was used as the dependent variable. Probability levels
<0.05 were considered signiﬁcant.
3. Results
3.1. General ﬁndings
Thirty-seven Saudi female patients were encountered during
the study period. Of these, 4 patients were excluded; 3 were
pregnant and one had hypothyroidism. Therefore, 33 SLE
female patients were enrolled in the study. The mean age
was 29.3 ± 9.5 years, ranged from 13 to 45 years. The mean
disease duration was 29.8 ± 18.4 months. Twenty-nine
(88%) out of the 33 studied SLE patients were classiﬁed as
active disease (SLEDAI> 4). hPRL was detected in 10 patients
(30.3%) with a mean serum PRL of 680.7 ± 1021.5 mIU/L
(range 198–4500 mIU/L, median 318 mIU/L) (Table 1).
3.2. Comparison between normoprolactinemic and
hyperprolactinemic patients
Table 2 illustrates the demographic, clinical, laboratory and
serological proﬁles of the normoprolactinemic (normoPRL)
Table 2 Clinical and laboratorial features of SLE patients
with and without hyperprolactinemia.
Variables Normoprolactinemic
n= 23
Hyperprolactinemic
n= 10
P
Age
(mean ± SD)
30.3 ± 9.7 27.1 ± 8.8 ns*
Disease
duration (ms)
29.2 ± 18 31.3 ± 20 ns*
Constitutional 5 (22%) 4 (40%) ns**
Articular 19 (83%) 10 (100%) ns**
Mucocutaneous 13 (56.5%) 8 (80%) ns**
Nephritis 8 (35%) 5 (50%) ns**
Serositis 7 (30%) 2 (20%) ns**
Vasculitis 4 (17%) 4 (40%) ns**
CNS lupus 9 (39%) 3 (30) ns**
APLs 2 (9%) 4 (40%) 0.03**
Active disease 19 (83%) 10 (100%) ns**
Thrombo-
cytopenia
3 (13%) 4 (40%) ns**
Leucopenia 6 (26%) 3 (30%) ns
Anemia 12 (52%) 5 (50%) ns**
Proteinuria 8 (35%) 5 (50%) ns**
Low
complement
11 (48%) 8 (80%) ns
Raised anti ds
DNA
8 (35%) 5 (50%) ns**
ESR 43 ± 27 58 ± 37 ns*
Serum PRL
(mean ± SD)
299 ± 95 1559 ± 1568 <0.0001*
CNS= central nervous system, APLs = antiphospholipid anti-
body syndrome, ds DNA= double stranded DNA,
ESR= erythrocyte sedimentation rate, PRL = prolactin.
P signiﬁcant <0.05.
ns = non signiﬁcant.
* t-test.
** X2 test.
hyperprolactinemia in systemic lupus erythematosus 79and hyperprolactinemic (hyperPRL) groups of patients. The
mean serum PRL in hyperPRL patients was signiﬁcantly high-
er than in normoPRL group, which were 1559 ± 1568 and
299 ± 95 mIU/L, respectively (P< 0.0001). Likewise, the
antiphospholipid antibody syndrome (APLs) was signiﬁcantly
prevalent in the hyperPRL group, P = 0.03. Although the
present study showed more frequent organ involvement and
higher trend to active disease in hyperPRL patients compared
to normoPRL group, this difference was not statistically
signiﬁcant.
3.3. Association of deﬁned disease manifestations with raised
serum PRL
Patients in the age group of 20 to <30 year exhibited higher
mean serum PRL compared to the other age groups; however,
this was not statistically signiﬁcant (f= 1.8, P= 0.18) (Fig. 1).
Signiﬁcant high mean serum PRL was observed among SLE
patients presented with fatigue or raised temperature
(P= 0.038), articular manifestations (P= 0.035), vasculitis
(P= 0.004), encephalopathy (P= 0.024), as well as patients
with APLs (P= 0.014). Similarly, thrombocytopenic patients
expressed higher mean serum PRL compared with non throm-
bocytopenic patients (1790 ± 1870.7 vs 381.9 ± 240.7). This
was statistically signiﬁcant, P< 0.0001 (Table 3).
3.4. Correlation of serum PRL levels with SLEDAI score,
clinical and laboratorial ﬁndings
Pearson’s correlation revealed no signiﬁcant correlation be-
tween the age of the patients, disease duration, SLEDAI score
and their serum PRL levels, P= 0.6, 0.7and 0.09, respectively.
Correlation was also tested between PRL level and anti ds
DNA titer and complement levels and 24 h urinary protein,
again no signiﬁcant correlation could be demonstrated. How-
ever, on the one hand, a statistically signiﬁcant negative
correlation between serum PRL and the platelet count was ob-
served (r= 0.5, P= 0.006); and a signiﬁcant positive corre-
lation was detected between serum PRL and the total
leukocytic count (r= 0.4, P= 0.035) and the body tempera-
ture (r= 0.4, P= 0.01) on the other hand.Table 1 Demographic data of the studied SLE patients.
Characteristics
Gender (F/M) 33/0
Mean age (years) (range) 29.3 ± 9.5 (13–45)
Age category n (%)
<20 6 (18.2%)
20 to <30 10 (30.3%)
30 to <40 12 (36.4%)
40 to <50 5 (15.2%)
Mean disease duration (ms) (range) 29.8 ± 18.4 (2–72)
Inpatient n (%) 17 (51.5%)
SLEDAI (median) (range) 20 (0–30)
Active disease n (%) 29 (88%)
hyperPRL n (%) 10 (30.3%)
Serum PRL mIU/L (median) (range) 318 (198–4500)
SLEDAI = SLE disease activity index.
PRL= prolactin.3.5. Linear regression analysis
Multiple linear stepwise regression analysis for serum PRL as
the dependent variable and the clinical, laboratory and sero-
logical features as the independent variables were done. The
procedure selected the platelet count and the total leukocytic
count as the best predictors of serum PRL level in the studied
Saudi SLE patients (R2 = 0.4, P= 0.002) (Fig. 2).
4. Discussion
Systemic lupus erythematosus (SLE) is an autoimmune dis-
ease, primarily, affecting young women of reproductive age.
The preponderance of SLE in women may result, in part, from
stimulation of the immune system by female hormones [9].
Prolactin is a polypeptide hormone that has wide spread ef-
fects on proliferation and differentiation of a variety of cells
in the immune system. Therefore, PRL could inﬂuence abnor-
mal immune regulation in SLE [4,7,9]. To the best of our
knowledge, this was the ﬁrst study exploring serum PRL levels
in Saudi SLE patients and its correlation to disease activity.
About 30% of the studied SLE patients in the current study
exhibited HPRL. This was in agreement with the previous
Bars show Mean
Figure 1 Mean serum prolactin in different age groups of the studied SLE patients (ANOVA, P> 0.05).
Table 3 Mean serum prolactin in SLE patients without and with deﬁned disease manifestations.
Variables Mean serum prolactin P*
Without n (mean ± SD) with n (mean ± SD)
Hospital admission 16 (817.7 ± 1207.9) 17 (1487.5 ± 1824.6) ns
Constitutional 24 (456.8 ± 429.5) 9 (1277.9 ± 1758.3) 0.038
Mucocutaneous 12 (453.3 ± 539) 21 (810.7 ± 1208.6) ns
Articular 4 (227 ± 9.2) 29 (743.2 ± 1076.6) 0.035**
Nephritis 20 (602.6 ± 953.2) 13 (800.9 ± 1148) ns
Serositis 24 (644.8 ± 925) 9 (776.3 ± 1303.2) ns
Vasculitis 25 (406.2 ± 381.8) 8 (1538.3 ± 1777.7) 0.004
CNS 21 (630.9 ± 919.8) 12 (767.9 ± 1218.2) ns
Encephalopathy 29 (533.7 ± 796.7) 4 (1746.2 ± 1866) 0.024
APLs 27 (542.9 ± 824.5) 6 (1300.7 ± 1605.9) 0.014
Active disease 4 (331.5 ± 129.9) 29 (728.9 ± 1082) ns
Thrombocytopenia 26 (381.9 ± 240.7) 7 (1790.4 ± 1870.7) <0.0001
Leucopenia 24 (794.5 ± 1180.3) 9 (377.2 ± 162) ns
Anemia 16 (438.9 ± 282.6) 17 (908.2 ± 1377.8) ns
Proteinuria 20 (602.6 ± 953.2) 13 (800.9 ± 1148) ns
Low complement 14 (624.6 ± 1120) 19 (722 ± 972) ns
Raised anti ds DNA 20 (600 ± 954.2) 13 (804.5 ± 1146) ns
CNS= central nervous system, APLs = antiphospholipid antibody syndrome, ds DNA= double stranded DNA, ESR= erythrocyte sedi-
mentation rate, PRL= prolactin.
P signiﬁcant at <0.05.
ns = non signiﬁcant.
* t-test.
** Fisher’s exact test.
80 D. Shahinstudies that reported HPRL in 10-33% of SLE patients
[10,12,14,15,20–22]. Higher frequencies were also observed
[16,23–25]. Hyperprolactinemia in patients with SLE may be
caused by either enhanced secretion of pituitary PRL underthe effect of inﬂammatory cytokines [26] or increased produc-
tion of PRL by peripheral lymphocytes [9,27]. Furthermore,
autoantibodies to PRL might be a potential cause of HPRL
in SLE patients [14,28]; owing to the reduced clearance of
Figure 2 The correlation between serum prolactin (dependent variable) and thrombocytopenia and leukocytosis (independent
predictors).
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[29] or its impaired penetration to the hypothalamus and a
subsequent disturbance of the hypothalamic pituitary feedback
mechanism [30].
Hyperprolactinemic patients in the presents study had sig-
niﬁcantly prevalent APLs. This was supported by Neidhart
[31], Jacobi [12], and recently by Jara et al. [13]. They
showed the association between hPRL in SLE patients and
APL antibodies, namely, anticardiolipin and/or lupus
anticoagulant.
There is a controversy about the existence of a correlation
between disease activity and the concentration of serum PRL
in SLE patients. Some authors reported these two parameters
to be positively correlated [10–13,20,21,25,32], whereas, others
denied an association [14–16,24,33–36]. In the current study,
the observed raised serum concentrations of PRL did not cor-
relate with the SLEDAI score for activity, nor with anti
ds-DNA titer; another marker of disease activity in SLE. Fur-
thermore, there was no signiﬁcant difference in disease activity
between hyperPRL and normoPRL patients in the present
study.
The conﬂicting results about the correlation between the
disease activity and the concentration of serum PRL might
be due to several potential causes such as lack of statistical
power [25], heterogeneity of the groups of patients studied, dif-
ferent indices used to measure SLE activity and variable assays
used for PRL measurement [7,9,37]. On the other hand, PRL
may not be a crucial factor in determining the disease activity
[15]. It is believed that SLE is such a polygenic disease, that
measurement of one biochemical factor is unlikely to reﬂect
the whole disease process.In a study by Lean˜os-Miranda et al. [28], the total serum
PRL levels did not correlate with the disease activity. Mean-
while, the free serum PRL correlated with the SLEDAI score
in the same study. Current evidences suggested that PRL com-
plexed with anti-PRL antibody or with any other molecule
forms big PRL that has attenuated biological activity, and
has been postulated to be a cause of HPRL in SLE patients
[28–30,38].
Of note, patients in the current study, with general signs of
illness, particularly raised temperature, articular manifesta-
tions, vasculitis, encephalopathy, APLs or thrombocytopenia
had signiﬁcantly higher mean values of serum PRL compared
to patients without these manifestations. In the Jacobi et al.
study [12], patients with raised temperature, fatigue, renal
involvement or anemia had signiﬁcantly higher serum PRL.
Similarly, participants, in the study of Rezaieyazdi et al. [21],
with malar rash and nephritis exhibited higher serum PRL
than participants without these manifestations. The PRL-
receptor had been identiﬁed in a number of cells and tissues
of adult mammals, including cells of the immune system, skin,
synovial membrane, chondrocytes, cartilage, kidney, central
nervous system, endothelial cells and retina [39,40], Binding
to the PRL-receptor is the initial step in the action of PRL [41].
Serum PRL levels in the present study correlated positively
with the total leukocytic count and the body temperature. One
explanation is that the immune system can synthesize PRL [7].
Another possible explanation is that PRL, itself, is a growth
factor for lymphocytes [8]. It is believed that PRL acts locally
to stimulate lymphocyte proliferation in an autocrine or para-
crine manner. Prolactin is thought to be a cytokine; the PRL-
receptor is a member of a novel receptor family that includes
82 D. Shahinreceptors for interleukin (IL) 2B, IL3, IL4 and IL6 and it
shares the intracellular signalization route with the other cyto-
kines [7,42,43].
However, El-Garf et al., [36] reported an inverse correlation
of leukocytic and lymphoid count and PRL levels in juvenile
SLE patients. Similarly, Haghighi et al. [10] found that leuco-
penia and thrombocytopenia were more frequent in HPRL pa-
tients. In line with these results, the platelet count inversely
correlated with PRL levels in the current study. Furthermore,
thrombocytopenia and leukocytosis were the best independent
predictors of raised serum PRL in the studied Saudi SLE
patients.
Therefore, bromocryptine, as an anti PRL [5], can be used
as a relatively safe adjunctive therapy in the treatment of recal-
citrant Saudi SLE patients, having thrombocytopenia and leu-
kocytosis, who are unresponsive to traditional approaches.
Additional investigations are needed to verify this hypothesis.
In conclusion hyperprolactinemia occurs in a subset of
Saudi SLE patients and can be predicted by the presence of
thrombocytopenia and leukocytosis. However, hyperprolacti-
nemia did not correlate with SLEDAI score for disease activity
in the studied patients. Studies involving larger cohort of lupus
patients are needed to clarify the possible role of PRL in the
regulation of immune responses and clinical expression in
SLE.Acknowledgment
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